Sodium Thiosulfate for Chemotherapy-Induced Hearing Loss
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will attempt to demonstrate the efficacy of Sodium Thiosulfate (STS) in preventing hearing loss in patients re-treated with cisplatin-based therapy according to regimens Cisplatin and STS (regimen CS) and Cisplatin, STS and Vorinostat/SAHA (regimen CSS).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must not have received myelosuppressive chemotherapy or immunotherapy within 2 weeks before joining the study. If you are on tacrolimus or sirolimus, your levels must be 10 ng/mL or lower.
Is sodium thiosulfate safe for humans?
Sodium thiosulfate has been studied for its ability to reduce hearing loss caused by certain chemotherapy drugs, like cisplatin, in children and adults. It has been approved in the USA for use in children to prevent hearing loss from chemotherapy, indicating it is generally considered safe for this purpose. However, in some animal studies, it showed potential neurotoxicity (harm to the nervous system) when administered immediately after certain treatments, suggesting timing of administration is important for safety.12345
How does the drug sodium thiosulfate differ from other treatments for chemotherapy-induced hearing loss?
Sodium thiosulfate is unique because it acts as an antioxidant that directly interacts with cisplatin, a chemotherapy drug, to prevent hearing loss without affecting its cancer-fighting ability. It is administered after chemotherapy and works by increasing antioxidant levels in cells, which helps protect against damage.12346
What data supports the effectiveness of the drug sodium thiosulfate for preventing chemotherapy-induced hearing loss?
Who Is on the Research Team?
James Geller, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Are You a Good Fit for This Trial?
This trial is for patients aged 1 month to 39 years with hepatoblastoma or certain other cancers, who have previously responded to cisplatin but now show progression or resistance. They must have a life expectancy of at least 8 weeks, good organ function, and no severe side effects from previous treatments. Pregnant women and those with heart failure or uncontrolled illnesses are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cisplatin-based therapy with Sodium Thiosulfate (STS) and possibly Vorinostat/SAHA for relapsed/refractory hepatoblastoma and other embryonal tumors
Follow-up
Participants are monitored for safety, prevention of hearing loss, and tumor response
What Are the Treatments Tested in This Trial?
Interventions
- Sodium Thiosulfate
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor